Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Aromatase inhibitor, Bisphosphonate, Breast cancer, GE-Lunar, Germany, Longitudinal, Secondary osteoporosis, Treatment (anti-osteoporotic treatments), Zoledronate
Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis. Austria, Bisphosphonate, Finite Elements Analysis, GE-Lunar, Ibandronate, Longitudinal, Sclerostin, Treatment (anti-osteoporotic treatments)
Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS). Alendronate, Bisphosphonate, Calcium, Denosumab, GE-Lunar, Longitudinal, Risedronate, Spain, Teriparatide, Testosterone, Treatment (anti-osteoporotic treatments), Vitamin D
[Primary hyperparathyroidism: new concepts, new recommendations] Bisphosphonate, Endocrinology, France, Hyperparathyroidism, Review, Secondary osteoporosis, Vitamin D
Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a Bisphosphonate, Hologic, Ibandronate, Longitudinal, Osteoporosis, Switzerland, Teriparatide, Treatment (anti-osteoporotic treatments)
Effects of anti-resorptive agents on trabecular bone score (TBS) in older women Antiresorptive therapy, Bisphosphonate, Calcitonin, Canada, GE-Lunar, Longitudinal, Raloxifene, Treatment (anti-osteoporotic treatments)
Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study Bisphosphonate, Hologic, Longitudinal, Osteoporosis, Switzerland, Treatment (anti-osteoporotic treatments), Zoledronate